These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 22177885)
1. [The new antidiabetic agents in the firing line.... safety reasons or witch hunt?]. Nicolau Ramis J; Masmiquel Comas L Endocrinol Nutr; 2012 Jan; 59(1):1-8. PubMed ID: 22177885 [No Abstract] [Full Text] [Related]
2. Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. Parks M; Rosebraugh C N Engl J Med; 2010 Mar; 362(9):774-7. PubMed ID: 20164475 [No Abstract] [Full Text] [Related]
3. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4? Xu L; Spinas GA; Niessen M Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848 [No Abstract] [Full Text] [Related]
4. GLP-1-based therapies: the dilemma of uncertainty. Spranger J; Gundert-Remy U; Stammschulte T Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985 [No Abstract] [Full Text] [Related]
5. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. Herman GA; Stein PP; Thornberry NA; Wagner JA Clin Pharmacol Ther; 2007 May; 81(5):761-7. PubMed ID: 17392725 [TBL] [Abstract][Full Text] [Related]
6. [Therapeutic use and adverse events of incretin-related drugs]. Ishikawa M; Yamada Y Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601 [No Abstract] [Full Text] [Related]
7. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333 [TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Madsbad S; Krarup T; Deacon CF; Holst JJ Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012 [TBL] [Abstract][Full Text] [Related]
9. Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. Cohen D BMJ; 2013 Apr; 346():f2607. PubMed ID: 23613543 [No Abstract] [Full Text] [Related]
10. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows. Cohen D BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395 [No Abstract] [Full Text] [Related]
11. Consumer group calls for antidiabetes drug to be withdrawn. Lenzer J BMJ; 2012 May; 344():e3259. PubMed ID: 22570213 [No Abstract] [Full Text] [Related]
12. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis? Olansky L Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512 [No Abstract] [Full Text] [Related]
13. The cage in search of a bird. Kalra S J Assoc Physicians India; 2012 Jan; 60():74-5. PubMed ID: 22715551 [No Abstract] [Full Text] [Related]
14. Liraglutide (Victoza) for type 2 diabetes. Med Lett Drugs Ther; 2010 Apr; 52(1335):25-7. PubMed ID: 20360660 [TBL] [Abstract][Full Text] [Related]
15. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone. Bailey CJ; Green BD; Flatt PR Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618 [TBL] [Abstract][Full Text] [Related]
16. Pioglitazone and bladder cancer: the pros and cons. Panikar V J Assoc Physicians India; 2012 Jan; 60():72-3. PubMed ID: 22715550 [No Abstract] [Full Text] [Related]
17. GLP-1 agonists and dipeptidyl-peptidase IV inhibitors. Gallwitz B Handb Exp Pharmacol; 2011; (203):53-74. PubMed ID: 21484567 [TBL] [Abstract][Full Text] [Related]
18. [DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. Gallwitz B Pharm Unserer Zeit; 2010 Mar; 39(2):114-8. PubMed ID: 20196038 [No Abstract] [Full Text] [Related]
19. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents. Fang V; Wazny LD; Raymond CB CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681 [No Abstract] [Full Text] [Related]
20. Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Langley AK; Suffoletta TJ; Jennings HR Pharmacotherapy; 2007 Aug; 27(8):1163-80. PubMed ID: 17655515 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]